TY - JOUR
T1 - Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53
AU - AK, Arya
AU - El-Fert, A
AU - Devling, T
AU - Eccles, RM
AU - Aslam, MA
AU - RUBBI, CARLOS
AU - Vlatkovic, N
AU - Fenwick, J
AU - Lloyd, BH
AU - Sibson, DR
AU - Jones, TM
AU - Boyd, MT
PY - 2010/6/29
Y1 - 2010/6/29
N2 - Primary radiotherapy (RT) is a mainstay of treatment for laryngeal squamous cell carcinoma (LSCC). Although the cure rates for early (T1) vocal cord tumours are high, RT proves ineffective in up to a third of T3 carcinomas. Moreover, RT is associated with debilitating early- and late-treatment-related toxicity, thus finding means to de-escalate therapy, while retaining/augmenting therapeutic effectiveness, is highly desirable. p53 is a key mediator of radiation responses; we therefore investigated whether Nutlin-3, a small-molecule inhibitor of MDM2 (mouse double minute 2; an essential negative regulator of p53), might radiosensitise LSCC cells.
AB - Primary radiotherapy (RT) is a mainstay of treatment for laryngeal squamous cell carcinoma (LSCC). Although the cure rates for early (T1) vocal cord tumours are high, RT proves ineffective in up to a third of T3 carcinomas. Moreover, RT is associated with debilitating early- and late-treatment-related toxicity, thus finding means to de-escalate therapy, while retaining/augmenting therapeutic effectiveness, is highly desirable. p53 is a key mediator of radiation responses; we therefore investigated whether Nutlin-3, a small-molecule inhibitor of MDM2 (mouse double minute 2; an essential negative regulator of p53), might radiosensitise LSCC cells.
U2 - 10.1038/sj.bjc.6605739
DO - 10.1038/sj.bjc.6605739
M3 - Article (journal)
SN - 0007-0920
VL - 103
SP - 186
EP - 195
JO - British Journal of Cancer
JF - British Journal of Cancer
ER -